Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer

Oncotarget



Volume 11, Issue 4

: In this study,

locally advanced head and neck cancer patients

undergoing definitive

chemoradiation

were randomly allocated to weekly cisplatin – radiation {CRT arm} or nimotuzumab -weekly cisplatin -radiation {NCRT arm}.

An interaction test was performed between the study arms and HPV status prior to doing any HPV specific analysis for each of the studied outcomes.

We had 187 HPV negative oropharyngeal cancers, 91 in the CRT arm and 96 in NCRT arm.

The addition of nimotuzumab to weekly cisplatin-radiation improves outcomes inclusive of OS in HPV negative oropharyngeal cancers.

Dr. Kumar Prabhash from

the Department of Medical Oncology at the Tata Memorial Hospital

, HBNI in Mumbai India said in their

Oncotarget

research article, “Locally advanced oropharyngeal cancers possess a unique challenge.”

Patients with HPV positive disease have a favorable prognosis as opposed to HPV negative disease.

They had hypothesized that an improvement in outcomes in our study was seen due to the differential patient population in our study when compared to the RTOG 0552 study.

Another phase 3 study, exploring the role of cetuximab along with

carboplatin

-5 FU with radiation, reported improvement in outcomes with the addition of

cetuximab

.

Taking this into consideration, the authors decided to perform a subgroup analysis of the HPV negative

oropharyngeal cancer

cohort, to study the absolute improvement in 2-year outcomes with the addition of

nimotuzumab.

The Prabhash Research Team concluded in

their

Oncotarget

article

that an interaction test was performed prior to doing the subgroup analysis, to determine whether nimotuzumab had a differential impact or not.

###

Sign up for free Altmetric alerts about this article

Full text –

https:/

/

doi.

org/

10.

18632/

oncotarget.

27443

Correspondence to – Kumar Prabhash –

[email protected]

Keywords – HPV negative, oropharynx, nimotuzumab, weekly, cisplatin

About

Oncotarget

Oncotarget

is a weekly, peer-reviewed, open-access biomedical journal covering research on all aspects of oncology.

To learn more about

Oncotarget

, please visit

http://www.

oncotarget.

com

or connect with @Oncotarget

Oncotarget

is published by Impact Journals, LLC please visit

http://www.

ImpactJournals.

com

or connect with @ImpactJrnls

Media Contact

18009220957×105


[email protected]